Elucidation of molecular basis of diversity in metabolic stress response of cancer cells for drug discovery
Project/Area Number |
16H04717
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Tumor therapeutics
|
Research Institution | Japanese Foundation for Cancer Research |
Principal Investigator |
TOMIDA Akihiro 公益財団法人がん研究会, がん化学療法センター ゲノム研究部, 部長 (40251483)
|
Research Collaborator |
TSUKAHARA satomi
SAKURAI junko
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2018: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
|
Keywords | 癌 / 分子標的治療 / 微小環境 / 代謝ストレス / 統合ストレス応答(ISR) / キナーゼ阻害剤 / 代謝ストレス剤 / UPR / ISR / キナーゼ阻害 / ストレス応答 / 多様性 |
Outline of Final Research Achievements |
Metabolic stress responses of cancer cells play an important role in cell survival and growth under various tumor-associated conditions. In this study, we focused on the diversity of activation mechanisms of integrated stress response (ISR) pathway among metabolic stress responses. By screening a kinase inhibitor library, we succeeded in identifying compounds that modulate oncogenic signals and control the ISR. Using these compounds, we further promoted research for establishing a novel therapeutic strategy that induces synthetic lethality through controlling the ISR.
|
Academic Significance and Societal Importance of the Research Achievements |
本研究の学術的特色・独創性は、がん細胞の代謝ストレス応答のなかで、がん化シグナルと密接に関連しがん細胞間で異なる反応がみられるものに注目し、がん特異的なストレス応答の制御法を開発しようという点にある。そして、ストレス応答を制御するツールとして、臨床に直結し得るキナーゼ阻害剤の同定に至っている。速やかな臨床応用の可能性も期待される本研究の成果は、新たながん治療法の開発という社会的要請に応えるものと位置づけられる。
|
Report
(4 results)
Research Products
(27 results)